Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
硕腾(US:ZTS) Businesswire·2025-10-29 20:30PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats. ...